Haemonetics Corp (HAE) Stock Price & Analysis
Haemonetics Corp (HAE) rose 1.78% to USD 78.78 as of July 25, 2026 at 08:27 UTC, according to Nexqual real-time market data.
HAE last closed at USD 77.4; the session ranged USD 77.48–79.41 on volume of 370,864 shares. Market capitalization is $3.58B, with a 52-week range of USD 47.32–87.32 (NYQ). Source: Nexqual, July 25, 2026 at 08:27 UTC.
Key Statistics (as of July 25, 2026 at 08:27 UTC)
| Price | USD 78.78 |
|---|---|
| Change | ▲ 1.78% (up) |
| Previous Close | USD 77.4 |
| Open | USD 78.32 |
| Day Range | USD 77.48 – 79.41 |
| 52-Week Range | USD 47.32 – 87.32 |
| Volume | 370,864 shares |
| Market Cap | $3.58B |
| Exchange | NYQ |
Technical Analysis (HAE)
Nexqual's technical model rates HAE "BUY" based on 5 bullish and 1 bearish signals across 125 daily candles, as of July 25, 2026 at 08:27 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 61.32 (neutral) |
| vs SMA50 | Above (USD 71.85) |
| MACD | 1.69 (positive) |
Analyst Ratings (HAE)
Wall Street analysts rate HAE "Buy" based on 10 analysts, with a mean price target of USD 86.6 (range USD 62–104), per Nexqual as of July 25, 2026 at 08:27 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 10 |
| Mean Target | USD 86.6 |
| High Target | USD 104 |
| Low Target | USD 62 |
| Buy / Hold / Sell | 8 / 3 / 0 |
Earnings (HAE)
| Next Earnings Date | 2026-08-06 |
|---|---|
| EPS Estimate | USD 1.08 |
| Revenue Estimate | $327.89M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD 1.29 vs est 1.27 ▲ beat |
| 2025-12-31 | USD 1.31 vs est 1.25 ▲ beat |
| 2025-09-30 | USD 1.27 vs est 1.11 ▲ beat |
| 2025-06-30 | USD 1.1 vs est 1.02 ▲ beat |
Source: Nexqual, July 25, 2026 at 08:27 UTC.
Financials & Fundamentals (HAE)
| Total Revenue | $1.33B |
|---|---|
| Revenue Growth (YoY) | +4.80% |
| Gross Margin | +59.43% |
| Operating Margin | +13.88% |
| Profit Margin | +7.29% |
| ROE | +12.03% |
| Debt / Equity | 160.08 |
| Current Ratio | 2.95 |
| Total Cash | $246.26M |
| Total Debt | $1.27B |
| Free Cash Flow | $298.09M |
Source: Nexqual, July 25, 2026 at 08:27 UTC.
Financial Health Score (HAE)
Nexqual rates Haemonetics Corp's overall financial health "Mixed" across five dimensions, as of July 25, 2026 at 08:27 UTC.
| Growth | Weak — Revenue -2% YoY (annual), declining |
|---|---|
| Profitability | Strong — Gross margin 59%, operating 14% |
| Balance Sheet | Weak — $246M cash vs $1.27B debt |
| Cash Flow | Strong — FCF $298M, 22% margin |
| Efficiency | Mixed — ROE 12%, ROA 6.5% |
Ownership (HAE)
| Insider Ownership | +1.22% |
|---|---|
| Institutional Ownership | +109.89% |
| Shares Outstanding | 45.45M |
| Float | 44.86M |
| Short % of Float | +8.06% |
Source: Nexqual, July 25, 2026 at 08:27 UTC.
Leadership (HAE)
Haemonetics Corp is led by Christopher A. Simon (age 61), CEO, President & Director, per Nexqual as of July 25, 2026 at 08:27 UTC.
| CEO, President & Director | Christopher A. Simon (age 61) |
|---|---|
| CFO, Executive VP & Financial Officer | James C. D'Arecca (age 54) |
| Executive VP & COO | Frank W. Chan (age 55) |
| Senior Director of Investor Relations | Olga Guyette |
| Senior Vice President of Strategy & Corporate Development | Rajeev Varma |
Major Backers & Investors (HAE)
Notable institutional backers of Haemonetics Corp include Neuberger Berman Group, LLC, AQR Capital Management, LLC, Arrowstreet Capital, Limited Partnership, according to Nexqual as of July 25, 2026 at 08:27 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Neuberger Berman Group, LLC | 11.12% |
| AQR Capital Management, LLC | 7.39% |
| Arrowstreet Capital, Limited Partnership | 3.04% |
| River Road Asset Management, LLC | 2.83% |
| FMR, LLC | 2.81% |
| Touchstone Strategic TRT-Touchstone Strategic TRT-Touchstone Small Com | 1.35% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 18.31% |
| Vanguard Group | 17% |
| State Street | 3.9% |
| Dimensional Fund Advisors | 2.92% |
Source: Nexqual, July 25, 2026 at 08:27 UTC.
From Haemonetics Corp's Latest SEC 10-K Filing (filed 2026-05-20)
Key Strengths & Strategy (as disclosed to the SEC)
- During fiscal 2026 we announced FDA clearance for the NexSys PCS Plasma Collection System with Persona PLUS technology, which represents the next generation of our proprietary and patented Persona technology that tailors plasma collections to each donor for improved average plasma volume per donation.
- Food and Drug Administration ("FDA") 510(k) clearance for our NexSys PCS with proprietary Persona ® technology.
- In fiscal 2024, we received FDA clearance for advancements to NexSys PCS including a new plasma collection bowl and new Express ® Plus technology engineered to reduce procedure time.
- Our innovative solutions addressing critical medical needs include a suite of hospital technologies designed to advance standards of care and help enhance outcomes for patients; end-to-end plasma collection technologies to optimize operations for plasma centers; and products to enable blood centers to collect in-demand blood components.
Partnerships
- In the U.S., allegations of such wrongful conduct could also result in a corporate integrity agreement with the U.S. government that imposes significant administrative obligations and costs. 11 Table of Contents Requirements Outside the U.S.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| ICUI | ICU Medical, Inc. | USD 157.44 | ▲ 0% |
| CNMD | CONMED Corporation | USD 42.68 | ▲ 1.62% |
| IART | Integra LifeSciences Holdings C | USD 19.79 | ▲ 5.15% |
| MMSI | Merit Medical Systems, Inc. | USD 74.32 | ▲ 1.66% |
| ITGR | Integer Holdings Corporation | USD 98.62 | ▲ 2.13% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 08:27 UTC. This page is informational and not investment advice.